NCT06296732 (ANLAP-R) is a clinical trial of Duration of surgery intervention in Neuroblastoma, sponsored by Federal Research Institute of Pediatric Hematology, Oncology and Immunology.

What drugs are being tested in NCT06296732?

Interventions in NCT06296732: Duration of surgery intervention.

What condition does NCT06296732 study?

NCT06296732 studies Neuroblastoma, Ganglioneuroma, Ganglioneuroblastoma.

Is NCT06296732 still recruiting?

NCT06296732 is currently recruiting now. Last updated 20 May 2024.

Last reviewed 2024-05-20 · How we verify

NCT06296732: ANLAP-R

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification

Recruiting now Last updated 20 May 2024

What this trial tests

trial testing Duration of surgery intervention in Neuroblastoma in 200 participants. Currently enrolling.

Timeline

19 October 2023

Primary endpoint
26 October 2026

1 November 2031

Quick facts

Lead sponsor	Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	200
Start date	19 October 2023
Primary completion	26 October 2026
Estimated completion	1 November 2031
Sites	1 location across Russia

Drugs / interventions tested

Duration of surgery intervention

Conditions studied

Neuroblastoma — all drugs for Neuroblastoma →
Ganglioneuroma — all drugs for Ganglioneuroma →
Ganglioneuroblastoma — all drugs for Ganglioneuroblastoma →

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Who can join

Adults 1 Day to 18, any sex, with Neuroblastoma or Ganglioneuroma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Surgery plays significant role in treatment of neurogenic tumors, both for benign ganglioneuroma and for high risk neuroblastoma. The world literature has accumulated large experience in laparoscopic surgery for abdominal neuroblastoma. The presence of IDRF (image-defined risk factors) and tumor size (\>4-7 cm) are considered as common contraindications for minimally invasive surgery in neuroblastoma. However, the recent studies have shown that presence of IDRF is not an absolute contraindication for laparoscopic surgery. This open-label, nonrandomized, observational, phase III evaluates role and weight of different surgical risk factors (including IDRF, tumor size, tumor localization, tumor volume/patient height ratio, previous open surgical procedures, previous chemotherapy etc.) in the laparoscopic neuroblastoma resections. The aim of this study is to create novel risk factors scoring system for laparoscopic surgery in abdominal neuroblastoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Neuroblastoma

Currently open trials in the same condition.

NCT07399821 — An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma · Phase 1, PHASE2 · recruiting
NCT06995872 — Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refra · Phase 1 · recruiting
NCT06942039 — Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation · EARLY_PHASE1 · recruiting
NCT07067346 — Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma · EARLY_PHASE1 · recruiting
NCT07027748 — Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or R · Phase 1 · recruiting

Other Federal Research Institute of Pediatric Hematology, Oncology and Immunology trials

Trials by the same sponsor.

NCT07316595 — Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage Syndrome · Phase 2 · not yet recruiting
NCT07375563 — Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Ris · Phase 3 · recruiting
NCT07366801 — Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus H · Phase 2, PHASE3 · recruiting
NCT07232134 — The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia · Phase 3 · recruiting
NCT06587191 — Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06296732 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Last refreshed: 20 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06296732.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing